| Year |
Citation |
Score |
| 2016 |
Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, Chook YM, Borden KL. Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E. Proceedings of the National Academy of Sciences of the United States of America. PMID 27114554 DOI: 10.1073/pnas.1524291113 |
0.302 |
|
| 2013 |
Culjkovic B, Fernando T, Yang S, Melnick AM, Borden KL, Cerchietti L. The Eukaryotic Translation Initiation Factor 4E (eIF4E) Has Oncogenic Functions and May Represent a New Therapeutic Target In Diffuse Large B Cell Lymphoma (DLBCL) Blood. 122: 3785-3785. DOI: 10.1182/blood.V122.21.3785.3785 |
0.317 |
|
| 2010 |
Volpon L, Osborne MJ, Capul AA, de la Torre JC, Borden KL. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. Proceedings of the National Academy of Sciences of the United States of America. 107: 5441-6. PMID 20212144 DOI: 10.1073/Pnas.0909877107 |
0.46 |
|
| 2009 |
Ploski JE, Topisirovic I, Park KW, Borden KL, Radu A. A mechanism of nucleocytoplasmic trafficking for the homeodomain protein PRH. Molecular and Cellular Biochemistry. 332: 173-81. PMID 19588232 DOI: 10.1007/S11010-009-0188-0 |
0.332 |
|
| 2007 |
Peng H, Gibson LC, Capili AD, Borden KL, Osborne MJ, Harper SL, Speicher DW, Zhao K, Marmorstein R, Rock TA, Rauscher FJ. The structurally disordered KRAB repression domain is incorporated into a protease resistant core upon binding to KAP-1-RBCC domain. Journal of Molecular Biology. 370: 269-89. PMID 17512541 DOI: 10.1016/j.jmb.2007.03.047 |
0.687 |
|
| 2005 |
Djavani M, Topisirovic I, Zapata JC, Sadowska M, Yang Y, Rodas J, Lukashevich IS, Bogue CW, Pauza CD, Borden KL, Salvato MS. The proline-rich homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus. Journal of Virology. 79: 2461-73. PMID 15681447 DOI: 10.1128/Jvi.79.4.2461-2473.2005 |
0.366 |
|
| 2005 |
Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Molecular and Cellular Biology. 25: 1100-12. PMID 15657436 DOI: 10.1128/Mcb.25.3.1100-1112.2005 |
0.63 |
|
| 2003 |
Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Molecular and Cellular Biology. 23: 8992-9002. PMID 14645512 DOI: 10.1128/Mcb.23.24.8992-9002.2003 |
0.416 |
|
| 2003 |
Seker H, Rubbi C, Linke SP, Bowman ED, Garfield S, Hansen L, Borden KL, Milner J, Harris CC. UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML. Oncogene. 22: 1620-8. PMID 12642865 DOI: 10.1038/Sj.Onc.1206140 |
0.31 |
|
| 2003 |
Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. The Embo Journal. 22: 689-703. PMID 12554669 DOI: 10.1093/Emboj/Cdg069 |
0.464 |
|
| 2002 |
Topisirovic I, Capili AD, Borden KL. Gamma interferon and cadmium treatments modulate eukaryotic initiation factor 4E-dependent mRNA transport of cyclin D1 in a PML-dependent manner. Molecular and Cellular Biology. 22: 6183-98. PMID 12167712 DOI: 10.1128/Mcb.22.17.6183-6198.2002 |
0.66 |
|
| 2002 |
Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Molecular and Cellular Biology. 22: 5259-69. PMID 12101223 DOI: 10.1128/Mcb.22.15.5259-5269.2002 |
0.455 |
|
| 2002 |
Strudwick S, Borden KL. The emerging roles of translation factor eIF4E in the nucleus. Differentiation; Research in Biological Diversity. 70: 10-22. PMID 11963652 DOI: 10.1046/J.1432-0436.2002.700102.X |
0.459 |
|
| 2001 |
Capili AD, Schultz DC, RauscherIII FJ, Borden KL. Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. The Embo Journal. 20: 165-77. PMID 11226167 DOI: 10.1093/Emboj/20.1.165 |
0.675 |
|
| 2000 |
Topcu Z, Borden KL. The yeast two-hybrid system and its pharmaceutical significance. Pharmaceutical Research. 17: 1049-55. PMID 11087035 DOI: 10.1023/A:1026493310144 |
0.351 |
|
| 2000 |
Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Prive GG, Licht JD. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Molecular and Cellular Biology. 20: 6550-67. PMID 10938130 DOI: 10.1128/Mcb.20.17.6550-6567.2000 |
0.391 |
|
| 2000 |
Lai HK, Borden KL. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene. 19: 1623-34. PMID 10763819 DOI: 10.1038/Sj.Onc.1203473 |
0.43 |
|
| 2000 |
Campbell Dwyer EJ, Lai H, MacDonald RC, Salvato MS, Borden KL. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner. Journal of Virology. 74: 3293-300. PMID 10708446 DOI: 10.1128/Jvi.74.7.3293-3300.2000 |
0.447 |
|
| 2000 |
Borden KL. RING domains: master builders of molecular scaffolds? Journal of Molecular Biology. 295: 1103-12. PMID 10653689 DOI: 10.1006/Jmbi.1999.3429 |
0.471 |
|
| 1999 |
Topcu Z, Mack DL, Hromas RA, Borden KL. The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control. Oncogene. 18: 7091-100. PMID 10597310 DOI: 10.1038/Sj.Onc.1203201 |
0.498 |
|
| 1998 |
Borden KL. RING fingers and B-boxes: zinc-binding protein-protein interaction domains. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 76: 351-8. PMID 9923704 DOI: 10.1139/Bcb-76-2-3-351 |
0.514 |
|
| 1998 |
Carlile GW, Tatton WG, Borden KL. Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. The Biochemical Journal. 335: 691-6. PMID 9794812 DOI: 10.1042/Bj3350691 |
0.375 |
|
| 1998 |
Borden KL. Structure/function in neuroprotection and apoptosis. Annals of Neurology. 44: S65-71. PMID 9749576 DOI: 10.1002/Ana.410440711 |
0.407 |
|
| 1998 |
Cao T, Duprez E, Borden KL, Freemont PS, Etkin LD. Ret finger protein is a normal component of PML nuclear bodies and interacts directly with PML. Journal of Cell Science. 111: 1319-29. PMID 9570750 |
0.419 |
|
| 1998 |
Borden KL, Campbelldwyer EJ, Carlile GW, Djavani M, Salvato MS. Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. Journal of Virology. 72: 3819-26. PMID 9557665 DOI: 10.1128/Jvi.72.5.3819-3826.1998 |
0.376 |
|
| 1998 |
Borden KL, Campbell Dwyer EJ, Salvato MS. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. Journal of Virology. 72: 758-66. PMID 9420283 DOI: 10.1128/Jvi.72.1.758-766.1998 |
0.467 |
|
| 1997 |
Borden KL, CampbellDwyer EJ, Salvato MS. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. Febs Letters. 418: 30-4. PMID 9414089 DOI: 10.1016/S0014-5793(97)01344-6 |
0.399 |
|
| 1997 |
Boddy MN, Duprez E, Borden KL, Freemont PS. Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodies. Journal of Cell Science. 110: 2197-205. PMID 9378769 |
0.404 |
|
| 1997 |
Cao T, Borden KL, Freemont PS, Etkin LD. Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution. Journal of Cell Science. 110: 1563-71. PMID 9247190 |
0.421 |
|
| 1996 |
Borden KL, Freemont PS. The RING finger domain: a recent example of a sequence-structure family. Current Opinion in Structural Biology. 6: 395-401. PMID 8804826 DOI: 10.1016/S0959-440X(96)80060-1 |
0.37 |
|
| 1996 |
Saurin AJ, Borden KL, Boddy MN, Freemont PS. Does this have a familiar RING? Trends in Biochemical Sciences. 21: 208-14. PMID 8744354 DOI: 10.1016/S0968-0004(96)80017-X |
0.524 |
|
| 1996 |
Borden KL, Lally JM, Martin SR, O'Reilly NJ, Solomon E, Freemont PS. In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML. Proceedings of the National Academy of Sciences of the United States of America. 93: 1601-6. PMID 8643677 DOI: 10.1073/Pnas.93.4.1601 |
0.421 |
|
| 1995 |
Borden KL, Boddy MN, Lally J, O'Reilly NJ, Martin S, Howe K, Solomon E, Freemont PS. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. The Embo Journal. 14: 1532-41. PMID 7729428 DOI: 10.1002/J.1460-2075.1995.Tb07139.X |
0.427 |
|
| 1994 |
Boddy MN, Freemont PS, Borden KL. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends in Biochemical Sciences. 19: 198-9. PMID 8048160 DOI: 10.1016/0968-0004(94)90020-5 |
0.478 |
|
| 1990 |
Borden KL, Richards FM. Folding of the reduced form of the thioredoxin from bacteriophage T4. Biochemistry. 29: 8207-10. PMID 2252882 DOI: 10.1021/Bi00488A002 |
0.464 |
|
| 1990 |
Borden KL, Richards FM. Folding kinetics of phage T4 thioredoxin. Biochemistry. 29: 3071-7. PMID 2186806 DOI: 10.1021/Bi00464A025 |
0.435 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2002 |
Strudwick S, Borden KL. Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia. 16: 1906-17. PMID 12357342 DOI: 10.1038/sj.leu.2402724 |
0.299 |
|
| 2001 |
Djavani M, Rodas J, Lukashevich IS, Horejsh D, Pandolfi PP, Borden KL, Salvato MS. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. Journal of Virology. 75: 6204-8. PMID 11390623 DOI: 10.1128/Jvi.75.13.6204-6208.2001 |
0.291 |
|
| 2017 |
Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchett-Cohen A, Osborne MJ, Borden KL. A biochemical framework for eIF4E-dependent mRNA export and nuclear re-cycling of the export machinery. Rna (New York, N.Y.). PMID 28325843 DOI: 10.1261/rna.060137.116 |
0.287 |
|
| 2016 |
Borden KL. The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions. Translation (Austin, Tex.). 4: e1220899. PMID 28090419 DOI: 10.1080/21690731.2016.1220899 |
0.284 |
|
| 2015 |
Osborne MJ, Borden KL. The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled. Immunological Reviews. 263: 210-23. PMID 25510279 DOI: 10.1111/imr.12240 |
0.281 |
|
| 2010 |
Hariri F, Arguello M, Culjkovic B, Amri A, Borden K. The Eukaryotic Translation Initiation Factor eIF4E, a Recently Identified Therapeutic Target In AML, Is a Direct Transcriptional Target of NFkB Blood. 116: 3146-3146. DOI: 10.1182/blood.v116.21.3146.3146 |
0.279 |
|
| 2011 |
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2874-84. PMID 21415224 DOI: 10.1158/1078-0432.Ccr-10-2334 |
0.269 |
|
| 2014 |
Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, ... ... Borden KL, et al. LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Research. 74: 1390-403. PMID 24590809 DOI: 10.1158/0008-5472.Can-13-1275 |
0.261 |
|
| 2014 |
Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden KL, Gartenhaus RB. MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL. Nature Communications. 5: 5413. PMID 25403230 DOI: 10.1038/ncomms6413 |
0.253 |
|
| 2009 |
Rolef Ben-Shahar T, Castillo AG, Osborne MJ, Borden KL, Kornblatt J, Verreault A. Two fundamentally distinct PCNA interaction peptides contribute to chromatin assembly factor 1 function. Molecular and Cellular Biology. 29: 6353-65. PMID 19822659 DOI: 10.1128/Mcb.01051-09 |
0.227 |
|
| 2015 |
Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, ... ... Borden KL, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. PMID 26603836 DOI: 10.1182/Blood-2015-05-645069 |
0.217 |
|
| 2013 |
Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL. Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate. Biochemical and Biophysical Research Communications. 434: 614-9. PMID 23583375 DOI: 10.1016/j.bbrc.2013.03.125 |
0.214 |
|
| 2015 |
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH, Borden KL. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica. 100: e7-9. PMID 25425688 DOI: 10.3324/Haematol.2014.111245 |
0.21 |
|
| 2009 |
Topisirovic I, Gutierrez GJ, Chen M, Appella E, Borden KL, Ronai ZA. Control of p53 multimerization by Ubc13 is JNK-regulated. Proceedings of the National Academy of Sciences of the United States of America. 106: 12676-81. PMID 19651615 DOI: 10.1073/Pnas.0900596106 |
0.172 |
|
| 2013 |
Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK, Borden KL. The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia. Leukemia. 27: 2047-55. PMID 23467026 DOI: 10.1038/Leu.2013.73 |
0.171 |
|
| 2009 |
Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, Borden KL. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 114: 257-60. PMID 19433856 DOI: 10.1182/Blood-2009-02-205153 |
0.159 |
|
| 2013 |
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Amri A, Gendron P, Romeo AA, Morris S, Jaquith J, Cormack G, Cocolakis E, Bergeron J, Cerchietti L, Leber B, Miller WH, Borden KL. A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1 Blood. 122: 821-821. DOI: 10.1182/Blood.V122.21.821.821 |
0.155 |
|
| 2012 |
Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, et al. MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo Cancer Cell. 22: 812-824. PMID 23238016 DOI: 10.1016/J.Ccr.2012.11.003 |
0.153 |
|
| 2015 |
Delaleau M, Borden KL. Multiple Export Mechanisms for mRNAs. Cells. 4: 452-73. PMID 26343730 DOI: 10.3390/cells4030452 |
0.143 |
|
| 2017 |
Zahreddine HA, Culjkovic-Kraljacic B, Emond A, Pettersson F, Midura R, Lauer M, Del Rincon S, Cali V, Assouline S, Miller WH, Hascall V, Borden K. The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity. Elife. 6. PMID 29111978 DOI: 10.7554/Elife.29830 |
0.134 |
|
| 2009 |
Culjkovic B, Borden KL. Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer. Journal of Oncology. 2009: 981679. PMID 20049173 DOI: 10.1155/2009/981679 |
0.127 |
|
| 2022 |
Borden K. The search for genetic dark matter and lessons learned from the journey. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. PMID 35658546 DOI: 10.1139/bcb-2022-0138 |
0.122 |
|
| 2011 |
Clozel T, Yang S, Kormaksson M, Elstrom R, Vasanthakumar A, Brennan S, Culjkovic B, Leser M, Martin P, Borden KL, Wang YL, Cheng S, Tam W, Shaknovich R, Chadburn A, et al. Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues Blood. 118: 1617-1617. DOI: 10.1182/Blood.V118.21.1617.1617 |
0.12 |
|
| 2011 |
Assouline S, Kraljacic-Culjkovic B, Cocolakis E, Amri A, Bergeron J, Jamal R, Miller WH, Borden KL. A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E, Blood. 118: 3606-3606. DOI: 10.1182/Blood.V118.21.3606.3606 |
0.113 |
|
| 2014 |
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, ... ... Borden KL, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511: 90-3. PMID 24870236 DOI: 10.1038/Nature13283 |
0.105 |
|
| 2013 |
Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, ... ... Borden KL, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discovery. 3: 1002-19. PMID 23955273 DOI: 10.1158/2159-8290.Cd-13-0117 |
0.102 |
|
| 2009 |
Borden KL, Culjkovic B. Understanding and targeting the eukaryotic translation initiation factor eif4E in head and neck cancer Journal of Oncology. DOI: 10.1155/2009/981679 |
0.102 |
|
| 2011 |
Déléris P, Trost M, Topisirovic I, Tanguay PL, Borden KL, Thibault P, Meloche S. Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway. The Journal of Biological Chemistry. 286: 6470-8. PMID 21177870 DOI: 10.1074/Jbc.M110.181529 |
0.096 |
|
| 2015 |
Zahreddine HA, Borden KL. Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2207-10. PMID 25810373 DOI: 10.1158/1078-0432.CCR-14-1370 |
0.09 |
|
| 2012 |
Assouline S, Cocolakis E, Borden KL. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers. 4: 1161-79. PMID 24213503 DOI: 10.3390/cancers4041161 |
0.082 |
|
| 2011 |
Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 25: 1197-200. PMID 21455212 DOI: 10.1038/leu.2011.57 |
0.082 |
|
| 2013 |
Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Frontiers in Pharmacology. 4: 28. PMID 23504227 DOI: 10.3389/fphar.2013.00028 |
0.07 |
|
| 2015 |
Zahreddine HA, Culjkovic-Kraljacic B, Borden KL. Sonic Hedgehog factor Gli1: As good as resistant. Molecular & Cellular Oncology. 2: e961827. PMID 27308395 DOI: 10.4161/23723548.2014.961827 |
0.064 |
|
| 2014 |
Culjkovic-Kraljacic B, Zahreddine HA, Borden KL. Inducible drug modification: a new form of resistance. Cell Cycle (Georgetown, Tex.). 13: 2485-6. PMID 25486186 DOI: 10.4161/15384101.2014.946372 |
0.059 |
|
| 2007 |
Grueber WB, Ye B, Yang CH, Younger S, Borden K, Jan LY, Jan YN. Projections of Drosophila multidendritic neurons in the central nervous system: links with peripheral dendrite morphology. Development (Cambridge, England). 134: 55-64. PMID 17164414 DOI: 10.1242/dev.02666 |
0.051 |
|
| 1999 |
Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1299-305. PMID 10389912 |
0.051 |
|
| 2012 |
Song D, Xiong J, Hu Z, Li G, Wang H, An H, Yu B, Grenko B, Borden K, Sauer K, Roessler T, Cui J, Bultman J, Vlooswijk AHG, Venema PR. Progress in n-type Si solar cell and module technology for high efficiency and low cost Conference Record of the Ieee Photovoltaic Specialists Conference. 3004-3008. DOI: 10.1109/PVSC.2012.6318216 |
0.047 |
|
| 2000 |
Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ. Sexuality and cancer: conversation comfort zone. The Oncologist. 5: 336-44. PMID 10965002 |
0.039 |
|
| 1988 |
Lynch DM, Briggman J, Borden K, Fritsche H, Malkin A. An enzyme immunoassay for carcinoembryonic antigen which employs simultaneous incubation of specimen with solid phase and enzyme-conjugated antibodies. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 9: 270-80. PMID 3057595 DOI: 10.1159/000217571 |
0.038 |
|
| 2006 |
O'Leary S, Burns T, Borden K. Performance of children with epilepsy and normal age-matched controls on the WISC-III Child Neuropsychology. 12: 173-180. PMID 16837393 DOI: 10.1080/09297040500276844 |
0.037 |
|
| 2004 |
Thompson AH, Borden K, Belton KL. Intentional and unintentional injuries across health Regions in Alberta, Canada: An implication for policy Crisis. 25: 156-160. PMID 15580850 DOI: 10.1027/0227-5910.25.4.156 |
0.036 |
|
| 2004 |
Borden K. Determining negotiating ranges for EDI-induced transaction and float cost reductions Global Finance Journal. 15: 71-79. DOI: 10.1016/j.gfj.2003.09.002 |
0.035 |
|
| 2015 |
Banfield JK, Wong OI, Willett KW, Norris RP, Rudnick L, Shabala SS, Simmons BD, Snyder C, Garon A, Seymour N, Middelberg E, Andernach H, Lintott CJ, Jacob K, Kapińska AD, ... ... Borden K, et al. Radio Galaxy Zoo: Host galaxies and radio morphologies derived from visual inspection Monthly Notices of the Royal Astronomical Society. 453: 2326-2340. DOI: 10.1093/Mnras/Stv1688 |
0.032 |
|
| 1969 |
Novak E, Borden K, Vitti T, Hearron M. Blood glucose and drug levels in normal fasting subjects following single oral doses of tolazamide and chlorpropamide Michigan Medicine. 68: 1243-1245. PMID 4901022 |
0.031 |
|
| 2000 |
Cummings GE, Voaklander D, Vincenten J, Policicchio C, Borden K. Emergency staff survey on their role in pediatric injury prevention education-a pilot study. The Journal of Emergency Medicine. 18: 299-303. PMID 10729666 DOI: 10.1016/S0736-4679(99)00218-8 |
0.023 |
|
| 2014 |
Borden KL. When will resistance be futile? Cancer Research. 74: 7175-80. PMID 25477336 DOI: 10.1158/0008-5472.CAN-14-2607 |
0.022 |
|
| 2006 |
Borden K, Burns T, O'Leary S. A comparison of children with epilepsy to an age- and IQ-matched control group on the Children's Memory Scale Child Neuropsychology. 12: 165-172. PMID 16837392 DOI: 10.1080/09297040500276836 |
0.02 |
|
| 2013 |
Maisel A, Barnard D, Jaski B, Frivold G, Marais J, Azer M, Miyamoto MI, Lombardo D, Kelsay D, Borden K, Iqbal N, Taub PR, Kupfer K, Clopton P, Greenberg B. Primary results of the HABIT Trial (heart failure assessment with BNP in the home). Journal of the American College of Cardiology. 61: 1726-35. PMID 23500322 DOI: 10.1016/j.jacc.2013.01.052 |
0.019 |
|
| 2014 |
Isaac ME, Anglaaere LCN, Borden K, Adu-Bredu S. Intraspecific root plasticity in agroforestry systems across edaphic conditions Agriculture, Ecosystems and Environment. 185: 16-23. DOI: 10.1016/j.agee.2013.12.004 |
0.012 |
|
| 2004 |
Colman I, Dryden DM, Thompson AH, Chahal AM, Borden K, Rowe BH, Voaklander DC. Utilization of the Emergency Department after Self-inflicted Injury Academic Emergency Medicine. 11: 136-142. PMID 14759954 DOI: 10.1197/j.aem.2003.08.016 |
0.01 |
|
| 2000 |
Voaklander DC, Cummings GE, Borden K, Policicchio C, Vincenten J. Pilot intervention to improve the documentation of pediatric injuries in the emergency department, Critical care medicine as a subspecialty of emergency medicine. Cjem. 2: 252-7. PMID 17612450 |
0.01 |
|
| 1997 |
Cooper JC, Borden K. The interpretation of wages and prices in public historical displays Public Historian. 19: 9-29. |
0.01 |
|
| Hide low-probability matches. |
